ANAL MARGIN SQUAMOUS CELL CARCINOMA
Clinical trials for ANAL MARGIN SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ANAL MARGIN SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for ANAL MARGIN SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope: personalized therapy for HIV patients with anal cancer
Disease control OngoingThis study tests a personalized approach for people with HIV and anal cancer. For low-risk patients, standard chemotherapy and radiation are used. For high-risk patients, the immunotherapy drug nivolumab is added after standard treatment to help prevent the cancer from coming bac…
Matched conditions: ANAL MARGIN SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:55 UTC
-
Could less be more? new study tests gentler treatment for anal cancer
Disease control OngoingThis study is for people with early-stage anal cancer. It compares a lower-dose chemotherapy and radiation treatment to the standard dose. The goal is to see if the lower dose works just as well to control the cancer but causes fewer side effects and improves quality of life. Abo…
Matched conditions: ANAL MARGIN SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 26, 2026 11:45 UTC
-
Immunotherapy after Chemo-Radiation may keep anal cancer at bay
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab after standard chemoradiation helps prevent anal cancer from coming back in patients with high-risk stage II-III disease. About 344 adults with certain types of anal cancer will receive nivolumab or a placebo for up…
Matched conditions: ANAL MARGIN SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:37 UTC